Home > Insider Trading > Filing (0001104659-24-089008)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1649904	Rhythm Pharmaceuticals Inc.	RYTM	Pharmaceutical Preparations (2834)	462159271

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1873517	J. Pamela Cramer	222 Berkeley Street 12Th Floor Boston MA 02116	Chief Human Resources Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2024-08-09	30,771	$19.02	62,506	No	4	M	Direct
Common Stock	Disposition	2024-08-09	46,902	$45.13	15,604	No	4	S	Direct
Common Stock	Disposition	2024-08-09	2,104	$45.62	13,500	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Options (Right to buy)	Disposition	2024-08-09	30,771	$0.00	30,771	$19.02

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
30,736		2031-07-25	No	4	M	Direct

Footnotes

The sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted on May 10, 2024.
The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $44.53 to $45.51. The Reporting Person undertakes to provide upon request the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.
The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $45.53 to $45.77. The Reporting Person undertakes to provide upon request the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.
The stock options were granted on July 26, 2021. 25% of the shares subject to the option vested and became exercisable on July 26, 2022 and the remaining 75% of the shares subject to the option vest or have vested and become exercisable in 12 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer thereafter.